MedTrace Logo

Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease

NCT00471393 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-11-05

No results posted yet for this study

Summary

The use of a topical medication was compared to placebo to be applied over the symptomatic temporomandibular joint in women with the diagnosis of osteoarthritis of the temporomandibular joint(s).

The hypothesis is to investigate whether the use of a topical anti-inflammatory medication when compared to the placebo would decrease the pain of the affected joint and/or increased mouth opening.

Conditions

  • Temporomandibular Degenerative Joint Disease

Interventions

DRUG

1.5% diclofenac in 45.5% DMSO (topical treatment)

DRUG

45.5% DMSO (topical placebo)

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Norman Thie, BSc DDS MSc · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Completion
2007-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471393 on ClinicalTrials.gov